LDS/Medical Tests/Cytochrome P450 2D6 (CYP2D6) Genotyping

Cytochrome P450 2D6 (CYP2D6) Genotyping

The cytochrome P450 (CYP450) enzymes catalyze the oxidation of many drugs and chemicals in our body. CYP450 is a large enzyme family mostly found in the liver. Since these enzymes have more than 50 isoenzymes (variations), their activity may vary from person to person. Individual differences of cytochrome P450 activity can result in variation from total absence or decreased metabolism of certain drugs to ultrafast or increased metabolism of drugs. This can lead to adverse drug reactions or a lack of therapeutic effect under standard therapy conditions.

CYP2D6 is gene 6 within the D subfamily, in the 2 family of CYP450. It metabolizes 25% of all prescribed drugs, such as codeine, tricyclic antidepressants (e.g., nortriptyline), SSRI fluvoxamine, SSNRI venlafaxine, classical antipsychotics (e.g., haloperidol), and beta-blockers. Four distinct phenotypes (observable variations) are found with regard to the enzyme's activity in the human body: normal metabolizers (NM), poor metabolizers (PM), intermediate metabolizers (IM), and ultra rapid metabolizers (URM).

CYP2D6 *1 and *2 are normal metabolizers, *3 through *6 are poor metabolizers and are the four most common alleles which account for approximately 95% of the mutations found in the Caucasian population. Intermediate metabolizers contain one functional and one mutant CYP2D6 alleles. Varying allele groups such as CYP2D6 *6 through *8, *11 through *16, *19 , *20 and *38 are known to lack enzyme activity for drugs such as dextromethorphan, sparteine, and bufarulol. This is a particularly rare combination of these alleles. Specific variants in this gene also influence the metabolism of the breast cancer drug tamoxifen in postmenopausal women. Genetic polymorphisms of CYP2D6 could be used to predict the altered enzyme activity and address the potential effects of metabolized drugs. The metabolism of drugs is also influenced by race, ethnicity, diet, and medications. All factors should be considered prior to initiating new therapy.

  • Determining therapeutic strategy for therapeutics that are metabolized by the CYP450 2D6 gene product (antidepressant and other metabolized drugs)
  • Monitor and manage antidepressant drug therapy
Four distinct phenotypes (observable characteristics) are found to express the enzyme activity in the human body: + Normal or extensive metabolizers (NM) with normal function + Poor metabolizers (PM) with no (absent) function + Intermediate metabolizers (IM) with reduced function, + Ultra rapid metabolizers (URM) increased function. CYP2D6 \*1* and \*2* are normal metabolizers, \*3 through \*6 are poor metabolizers and are the four most common alleles which account for approximately 95% of the mutations found in the Caucasian population. Intermediate metabolizers contain one functional and one mutant CYP2D6 alleles. Varying allele groups such as CYP2D6 \*6 through \*8, \*11 through \*16, \*19 , \*20 and \*38 are known to lack enzyme activity in drugs such as dextromethorphan, sparteine, and bufarulol. The following is a list of major therapeutic classes with drugs that are substantially metabolized by CYP2D6: NSAIDs: tamoxifen Beta Blockers: carvedilol, S-metoprolol, propafenone, timolol Antidepressants: amitriptyline, clomipramine, desipramine, fluoxetine, imipramine, paroxetine, venlafaxine Antipsychotics: haloperidol, perphenazine, risperidone,thioridazine, zuclopenthixol, alprenolol, amphetamine, aripiprazole, atomoxetine, bufuralol, chlorpheniramine, chlorpromazine, clonidine, codeine, debrisoquine, dexfenfluramine, dextromethorphan, donepezil, duloxetine, encainide, flecainide, fluvoxamine, lidocaine, metoclopramide, methoxyamphetamine, mexiletine, minaprine, nebivolol, nortriptyline, ondansetron, oxycodone, perhexiline, phenacetin, phenformin, promethazine, propranolol, sparteine, tramadol The following is a list of major inhibitors that compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective. A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance. This include: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. This include:duloxetine, sertraline, terbinafine A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance. This include: amiodarone, cimetidine, celecoxib, chlorpheniramine, chlorpromazine, citalopram, clemastine, clomipramine, cocaine, diphenhydramine, doxepin, doxorubicin, escitalopram, halofantrine, hydroxyzine, levomepromazine, methadone, metoclopramide, mibefradil, midodrine, moclobemide, perphenazine, ranitidine, ritonavir, ticlopidine, tripelennamine

CYP2D6 \*1/\*1 (Normal Metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Blood (EDTA), buccal swab, saliva. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days

 

Drug toxicity if indicated, Liver function studies.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login